NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column purchased 50,000 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were purchased at an average cost of $13.50 per share, for a total transaction of $675,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of NYSE NGM traded down $0.09 during mid-day trading on Thursday, reaching $14.73. 611 shares of the company’s stock were exchanged, compared to its average volume of 110,491. NGM Biopharmaceuticals has a twelve month low of $12.00 and a twelve month high of $18.75.
A number of equities research analysts have recently commented on NGM shares. Citigroup started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $29.00 price target on the stock. Goldman Sachs Group started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Cowen started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set an “outperform” rating and a $25.00 price target on the stock.
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.
Featured Article: Percentage Decliners
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.